Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Vaccines

Free Subscription 22.07.2024 3 Ann Intern Med 1 Arch Virol 1 BMJ 1 Clin Infect Dis 1 Clin Microbiol Rev 1 Infect Immun 2 J Immunol 5 J Infect 2 J Infect Dis 1 J Virol 1 N Engl J Med 2 Nat Med 1 Pediatrics 1 PLoS Comput Biol 9 PLoS One 30 Vaccine 5 Virology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Intern Med

1. FUJIEDA T, Tanimoto T
   Communicating the Value of Influenza Vaccines to Patients.
   Ann Intern Med. 2024;177:990-991.
   PubMed        
   
   
2. SCHATTNER A
   Communicating the Value of Influenza Vaccines to Patients.
   Ann Intern Med. 2024;177:990.
   PubMed        
   
   
3. TENFORDE MW, Dawood FS
   Communicating the Value of Influenza Vaccines to Patients.
   Ann Intern Med. 2024;177:991.
   PubMed        
   
   

   
   Arch Virol

4. LIU C, Li S, Qiao M, Zeng C, et al
   GB and gH/gL fusion machinery: a promising target for vaccines to prevent Epstein-Barr virus infection.
   Arch Virol. 2024;169:167.
   PubMed         Abstract available
   
   

   
   BMJ

5. MAGNUS MC, Soderling J, Ortqvist AK, Andersen AN, et al
   Covid-19 infection and vaccination during first trimester and risk of congenital anomalies: Nordic registry based study.
   BMJ. 2024;386:e079364.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

6. ROMINE JK, Li H, Coughlin MM, Jones JM, et al
   Hybrid immunity and SARS-CoV-2 antibodies: results of the HEROES-RECOVER prospective cohort study.
   Clin Infect Dis. 2024 Mar 11:ciae130. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Clin Microbiol Rev

7. AHMED S, Herschhorn A
   mRNA-based HIV-1 vaccines.
   Clin Microbiol Rev. 2024 Jul 17:e0004124. doi: 10.1128/cmr.00041.
   PubMed         Abstract available
   
   

   
   Infect Immun

8. BITZER GJ, Fitzgerald NA, DeJong MA, Cunningham C, et al
   Immunization with an mRNA DTP vaccine protects against pertussis in rats.
   Infect Immun. 2024 Jul 17:e0052023. doi: 10.1128/iai.00520.
   PubMed         Abstract available
   
   

   
   J Immunol

9. DUROJAYE O, Vankayalapati A, Paidipally P, Mukherjee T, et al
   Lung-resident CD3-NK1.1+CD69+CD103+ Cells Play an Important Role in Bacillus Calmette-Guerin Vaccine-Induced Protective Immunity against Mycobacterium tuberculosis Infection.
   J Immunol. 2024 Jul 15:ji2200728. doi: 10.4049/jimmunol.2200728.
   PubMed         Abstract available
   
   
10. DANGI T, Sanchez S, Awakoaiye B, Lew MH, et al
    Breast Milk-Derived Antibodies Impair Vaccine Immunity in Suckling Mice.
    J Immunol. 2024 Jul 15:ji2400277. doi: 10.4049/jimmunol.2400277.
    PubMed         Abstract available
    
    

    
    J Infect

11. ANDREWS N, Osuntoki I, Stowe J, Kirsebom FCM, et al
    The impact of Covid-19 vaccine spring boosters on Covid-19 hospital admissions in England 2022/23.
    J Infect. 2024 Jul 10:106221. doi: 10.1016/j.jinf.2024.106221.
    PubMed         Abstract available
    
    
12. GRISKAITIS M, Thielemann I, Schonfeld V, Falman A, et al
    Effectiveness and duration of protection of primary and booster immunisation against meningococcal serogroup C disease with meningococcal conjugate C and ACWY vaccines: Systematic review.
    J Infect. 2024;89:106228.
    PubMed         Abstract available
    
    
13. PEREZ-GARCIA C, Sempere J, de Miguel S, Hita S, et al
    Surveillance of invasive pneumococcal disease in Spain exploring the impact of the COVID-19 pandemic (2019-2023).
    J Infect. 2024;89:106204.
    PubMed         Abstract available
    
    
14. MIKOLAJCZYK R, Diexer S, Klee B, Pfrommer L, et al
    Likelihood of Post-COVID Condition in people with hybrid immunity; data from the German National Cohort (NAKO).
    J Infect. 2024 Jun 17:106206. doi: 10.1016/j.jinf.2024.106206.
    PubMed         Abstract available
    
    
15. CLARK SA, Campbell H, Ribeiro S, Bertran M, et al
    Epidemiological and strain characteristics of invasive meningococcal disease prior to, during and after COVID-19 pandemic restrictions in England.
    J Infect. 2023 Sep 7:S0163-4453(23)00504-2. doi: 10.1016/j.jinf.2023.
    PubMed         Abstract available
    
    

    
    J Infect Dis

16. HILL-BATORSKI L, Weiner JA, Ackerman ME, Hatta Y, et al
    Intranasal M2SR (M2-deficient Single Replication) Influenza Vaccine Induces Broadly Reactive Mucosal Antibody Production in Adults.
    J Infect Dis. 2024 Jul 16:jiae361. doi: 10.1093.
    PubMed         Abstract available
    
    
17. LACABARATZ C, Durand M, Wiedemann A, Foucat E, et al
    Innate and cellular immune response to the Ebola vaccine Ad26.ZEBOV, MVA-BN-Filo: an ancillary study of the EBL2001 phase II trial.
    J Infect Dis. 2024 Jul 16:jiae360. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Virol

18. MCMILLEN CM, Megli C, Radisic R, Skvarca LB, et al
    Vaccine strains of Rift Valley fever virus exhibit attenuation at the maternal-fetal placental interface.
    J Virol. 2024 Jul 17:e0098324. doi: 10.1128/jvi.00983.
    PubMed         Abstract available
    
    

    
    N Engl J Med

19. ROSEN CJ
    Viral Variants, Vaccinations, and Long Covid - New Insights.
    N Engl J Med. 2024 Jul 17. doi: 10.1056/NEJMe2407575.
    PubMed        
    
    

    
    Nat Med

20. KHURANA S, King LR, Manischewitz J, Posadas O, et al
    Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus.
    Nat Med. 2024 Jul 16. doi: 10.1038/s41591-024-03189.
    PubMed         Abstract available
    
    
21. MAY M
    How mRNA is powering a personalized vaccine revolution.
    Nat Med. 2024 Jul 15. doi: 10.1038/d41591-024-00052.
    PubMed        
    
    

    
    Pediatrics

22. KHAZANCHI R, Rader B, Cantor J, McManus KA, et al
    Spatial Accessibility and Uptake of Pediatric COVID-19 Vaccinations by Social Vulnerability.
    Pediatrics. 2024 Jul 19:e2024065938. doi: 10.1542/peds.2024-065938.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

23. DOYLE NJ, Cumming F, Thompson RN, Tildesley MJ, et al
    When should lockdown be implemented? Devising cost-effective strategies for managing epidemics amid vaccine uncertainty.
    PLoS Comput Biol. 2024;20:e1012010.
    PubMed         Abstract available
    
    

    
    PLoS One

24. VAN DEN BOSSCHE J, De Laere M, Deschepper K, Germonpre P, et al
    Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.
    PLoS One. 2024;19:e0307204.
    PubMed         Abstract available
    
    
25. LEE J, Lee CW, Suarez DL, Lee SA, et al
    Efficacy of commercial recombinant HVT vaccines against a North American clade 2.3.4.4b H5N1 highly pathogenic avian influenza virus in chickens.
    PLoS One. 2024;19:e0307100.
    PubMed         Abstract available
    
    
26. NOURANI L, Mehrizi AA, Zakeri S, Djadid ND, et al
    Correction: Untangling population structure and genetic diversity of reticulocyte binding protein 2b (PvRBP2b) erythrocytic stage vaccine candidate in worldwide Plasmodium vivax isolates.
    PLoS One. 2024;19:e0307447.
    PubMed         Abstract available
    
    
27. 
    Retraction: Entrapment of H1N1 Influenza Virus Derived Conserved Peptides in PLGA Nanoparticles Enhances T Cell Response and Vaccine Efficacy in Pigs.
    PLoS One. 2024;19:e0307483.
    PubMed        
    
    
28. HOY C, Wood T, Moscoe E
    Correction: Addressing vaccine hesitancy in developing countries: Survey and experimental evidence.
    PLoS One. 2024;19:e0307570.
    PubMed         Abstract available
    
    
29. QUEE FA, Hogema BM, Molier M, Slot E, et al
    The Elecsys(R) Anti-SARS-CoV-2 and Elecsys(R) Anti-SARS-CoV-2 S antibody assays: Differentiating between vaccination and infection, and assessing long-term performance.
    PLoS One. 2024;19:e0305613.
    PubMed         Abstract available
    
    
30. MANSOUR AA, Hussein SM, Felemban SG, Mahamid AW, et al
    Correction: Acceptance and hesitancy of parents to vaccinate children against coronavirus disease 2019 in Saudi Arabia.
    PLoS One. 2024;19:e0307674.
    PubMed         Abstract available
    
    
31. ZEHRA A, Jamil S, Farman M, Nisar KS, et al
    Modeling and analysis of Hepatitis B dynamics with vaccination and treatment with novel fractional derivative.
    PLoS One. 2024;19:e0307388.
    PubMed         Abstract available
    
    
32. SALAZAR JC, Vargas-Cely F, Garcia-Luna JA, Ramirez LG, et al
    Treponema pallidum genetic diversity and its implications for targeted vaccine development: A cross-sectional study of early syphilis cases in Southwestern Colombia.
    PLoS One. 2024;19:e0307600.
    PubMed         Abstract available
    
    

    
    Vaccine

33. CHAU M, Kaufman J, Holland P, Danchin M, et al
    Co-designing an intervention to improve the childhood catch-up vaccination process for migrant parents in Australia.
    Vaccine. 2024 Jul 18:S0264-410X(24)00745-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
34. BAUER BU, Herms TL, Jahnke R, Ossowski N, et al
    Control of Coxiella burnetii shedding in a dairy goat herd by annual offspring vaccination.
    Vaccine. 2024 Jul 18:S0264-410X(24)00787-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
35. WASSIL J, Sisti M, Fairman J, Rankin B, et al
    A phase 2, randomized, blinded, dose-finding, controlled clinical trial to evaluate the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults 65 years and older.
    Vaccine. 2024 Jul 17:S0264-410X(24)00786-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
36. ANDERSON S, Kuter BJ, Brien K, Bauerle Bass S, et al
    Perceptions of vaccine requirements among students at four Pennsylvania universities.
    Vaccine. 2024 Jul 17:S0264-410X(24)00801-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
37. JIN CHOI S, Lee W, Cheol Kim S, Jo HY, et al
    Longitudinal multiomic profiling and corticosteroid modulation of the immediate innate immune response to an adenovirus-vector vaccine.
    Vaccine. 2024 Jul 17:S0264-410X(24)00774-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
38. SANTIBANEZ TA, Black CL, Zhou T, Srivastav A, et al
    Parental hesitancy about COVID-19, influenza, HPV, and other childhood vaccines.
    Vaccine. 2024 Jul 16:S0264-410X(24)00802-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
39. HU TH, Tou CY, Lee YH, Chang HH, et al
    Knowledge gap of human monkeypox among high-risk individuals receiving preexposure vaccination in Taiwan.
    Vaccine. 2024 Jul 16:S0264-410X(24)00753-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
40. JIN F, Zhu L, Wang Y, Qin G, et al
    Corrigendum to "Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic" [Vaccine (2024) 26059].
    Vaccine. 2024 Jul 16:S0264-410X(24)00791-6. doi: 10.1016/j.vaccine.2024.
    PubMed        
    
    
41. LIU G, Pang Y, Lv M, Lu M, et al
    Effectiveness of influenza vaccination on hospitalization outcomes among older patients with diabetes.
    Vaccine. 2024 Jul 16:S0264-410X(24)00806-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
42. STEENACKERS K, Hanning N, Bruckers L, Desombere I, et al
    Humoral immune response against SARS-CoV-2 after adapted COVID-19 vaccine schedules in healthy adults: The IMCOVAS randomized clinical trial.
    Vaccine. 2024 Jul 16:S0264-410X(24)00773-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
43. CERNUSCHI T, Malvolti S, Hall S, Debruyne L, et al
    The quest for more effective vaccine markets - Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic.
    Vaccine. 2024;42 Suppl 1:S64-S72.
    PubMed         Abstract available
    
    
44. PATEL MK, Scobie HM, Serhan F, Dahl B, et al
    A global comprehensive vaccine-preventable disease surveillance strategy for the immunization Agenda 2030.
    Vaccine. 2024;42 Suppl 1.
    PubMed         Abstract available
    
    
45. WONODI C, Crowcroft N, Bose AS, Oteri J, et al
    Country ownership as a guiding principle for IA2030: A case study of the measles and rubella elimination programs in Nepal and Nigeria.
    Vaccine. 2024;42 Suppl 1:S107-S117.
    PubMed         Abstract available
    
    
46. GARCIA S, Shin M, Gill M, He Z, et al
    Identifying the intersection of parental HPV and COVID-19 vaccine hesitancy to inform health messaging interventions in community-based settings.
    Vaccine. 2024 Jul 11:S0264-410X(24)00792-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
47. MILLER E, Michel A, Singh P, Limaye R, et al
    Countering vaccine misinformation: Designing a learning resource for healthcare workers in eight countries.
    Vaccine. 2024 Jul 11:S0264-410X(24)00732-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
48. LUNA-MUSCHI A, Carmo Borges I, Dos Santos Barboza A, de Faria E, et al
    Duration of vaccine protection against breakthrough infections during five COVID-19 waves among healthcare workers primarily vaccinated with CoronaVac.
    Vaccine. 2024 Jul 16:S0264-410X(24)00752-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
49. TAKAHASHI Y, Tanaka H, Taniguchi C, Ogata T, et al
    Efficiency of indirect protection of COVID-19 vaccination and interactions between indirect and direct protection on household transmission.
    Vaccine. 2024 Jul 16:S0264-410X(24)00749-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
50. HATFIELD K, Wiegand R, Reddy S, Patel A, et al
    Effectiveness of COVID-19 bivalent vaccination against SARS-CoV-2 infection among residents of US nursing homes, November 2022 - March 2023.
    Vaccine. 2024 Jul 16:S0264-410X(24)00754-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
51. ALTAWALBEH SM, Wateska AR, Patricia Nowalk M, Lin CJ, et al
    Corrigendum to "Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older" [Vaccine 42 (2024) 3024-3032].
    Vaccine. 2024 Jul 15:S0264-410X(24)00789-8. doi: 10.1016/j.vaccine.2024.
    PubMed        
    
    
52. STEFANIZZI P, Di Lorenzo A, Capodiferro L, Moscara L, et al
    Increasing vaccination coverage among healthcare workers: Active call and mandatory laws. Data from a large general hospital in Southern Italy.
    Vaccine. 2024 Jul 15:S0264-410X(24)00739-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
53. FISMAN DN, Simmons AE, Tuite AR
    Case-cohort design as an efficient approach to evaluating COVID-19 vaccine effectiveness, waning, heterologous immune effect and optimal dosing interval.
    Vaccine. 2024 Jul 13:S0264-410X(24)00797-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
54. JAJOU R, Lieber T, van Puijenbroek EP, Mulder E, et al
    GP consultations for menstrual disorders after COVID-19 vaccination - A self-controlled cohort study based on routine healthcare data from the Netherlands.
    Vaccine. 2024 Jul 13:S0264-410X(24)00793-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
55. DULL PM, Achilles SL, Ahmed R, Barnabas RV, et al
    Meeting report: Considerations for trial design and endpoints in licensing therapeutic HPV16/18 vaccines to prevent cervical cancer.
    Vaccine. 2024 Jul 13:S0264-410X(24)00741-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
56. VERANI JR, Omondi D, Odoyo A, Odiembo H, et al
    Long-term impact of 10-valent pneumococcal conjugate vaccine in Kenya: Nasopharyngeal carriage among children in a rural and an urban site six years after introduction.
    Vaccine. 2024 Jul 13:S0264-410X(24)00782-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
57. MIAO Q, Nguyen W, Zhu J, Liu G, et al
    A getah virus-like-particle vaccine provides complete protection from viremia and arthritis in wild-type mice.
    Vaccine. 2024 Jul 13:S0264-410X(24)00799-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
58. LE BAGOUSSE-BERNARD A, Dussart C, Pin P, Tazarourte K, et al
    Mass COVID-19 vaccination center: Optimizing the vaccination pathway during a 12 month timeframe.
    Vaccine. 2024 Jul 12:S0264-410X(24)00742-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
59. HUANG WT, Law B, Tran H, Schonborn L, et al
    Validation of the newly proposed Brighton Collaboration case definition for vaccine-induced immune thrombocytopenia and thrombosis.
    Vaccine. 2024 Jul 12:S0264-410X(24)00794-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
60. JOHNSTON C, Scheele S, Bachmann L, Boily MC, et al
    Vaccine value profile for herpes simplex virus.
    Vaccine. 2024;42.
    PubMed         Abstract available
    
    
61. MARTIN LB, Tack B, Marchello CS, Sikorski MJ, et al
    Vaccine value profile for invasive non-typhoidal Salmonella disease.
    Vaccine. 2024;42.
    PubMed         Abstract available
    
    
62. HOEVE CE, Huiberts AJ, de Gier B, Andeweg SP, et al
    COVID-19 vaccination-induced antibody responses and waning by age and comorbidity status in a large population-based prospective cohort study.
    Vaccine. 2024 Jul 11:S0264-410X(24)00783-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    

    
    Virology

63. LI S, Tang X, Zhou J, Bian X, et al
    The synergy of recombinant NSP4 and VP4 from porcine rotavirus elicited a strong mucosal response.
    Virology. 2024;597:110130.
    PubMed         Abstract available
    
    
64. KIM J, Villar Z, Jobe O, Rerks-Ngarm S, et al
    Broadly neutralizing antibodies and monoclonal V2 antibodies derived from RV305 inhibit capture and replication of HIV-1.
    Virology. 2024;597:110158.
    PubMed         Abstract available
    
    
65. ZHU H, Li X, Li X, Chen H, et al
    Protection against the H1N1 influenza virus using self-assembled nanoparticles formed by lumazine synthase and bearing the M2e peptide.
    Virology. 2024;597:110162.
    PubMed         Abstract available
    
    
66. LEI Y, Xu N, Niu C, Chen L, et al
    Specific immunological characteristics and risk factor of XBB variants re-infection in nasopharyngeal carcinoma patients after BA.5 infection.
    Virology. 2024;597:110142.
    PubMed         Abstract available
    
    
67. HUANG WC, Baker WS, Lovell JF, Schein CH, et al
    Displaying alphavirus physicochemical consensus antigens on immunogenic liposomes enhances antibody elicitation in mice.
    Virology. 2024;597:110152.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.